AHA releases late-breaking clinical trials schedule for annual Scientific Sessions
The American Heart Association (AHA) has announced the late-breaking clinical trials for its annual Scientific Sessions.
The conference takes place from Nov. 12 to Nov. 16 at the Ernest N. Morial Convention Center in New Orleans.
Here is a schedule of the late-breaking studies (all times are Central Standard Time):
Sunday, Nov. 13 – presentations from 3:45 p.m. to 5:00 p.m.
* EUCLID – Effects of Ticagrelor Compared with Clopidogrel in Patients with Peripheral Artery Disease – presenting researcher is Manesh Patel, MD, of the Duke Clinical Research Institute and Duke University in Durham, North Carolina
* PRECISION – Cardiovascular Outcomes with Celecoxib vs. Ibuprofen or Naproxen – presenting researcher is Steve Nissen, MD, of the Cleveland Clinic in Cleveland, Ohio
* HOPE-3 – The Effect of Blood Pressure and Cholesterol Lowering on Cognition – the presenting researcher is Jackie Bosch, MD, of McMaster University in Hamilton, Ontario, Canada
* TRUE AHF – Short- and Long-Term Effect of Immediate Vasodilator Therapy in Acutely Decompensated Heart Failure – the presenting researcher is Milton Packer, MD, of Baylor Heart and Vascular Institute and Baylor University Medical Center in Waco, Texas
Monday, Nov. 14 – presentations from 10:45 a.m. to 12:00 p.m.
* ART – Randomized Comparison of Single Versus Bilateral Internal Mammary Artery Grafting in 2102 Patients: Effects on Major Cardiovascular Outcomes After Five Years Follow Up – the presenting researcher is David Taggart, MD, of the University of Oxford in the United Kingdom
* FUTURE - The Functional Testing Underlying Coronary Revascularization Study: A "Real World" Comparison of Fractional Flow Reserve-Guided Management Versus Conventional Management in Multi Vessel Coronary Artery Disease Patients - the presenting researcher is Gilles Rioufol, MD, of Hospices Civils de Lyon in France
* PIONEER AF-PCI – An Open-label, Randomized, Controlled, Multicenter Study Exploring Two TreatmeNt Strategies of Rivaroxaban and a Dose- Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention – the presenting researcher is C. Michael Gibson, MD, of Beth Israel Deaconess Medical Center in Boston
* GERMANY – Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve replacement for severe symptomatic aortic valve stenosis One Year results from the German Aortic Valve Registry – the presenting researcher is Nicolas Werner, MD, of Ludwigshafen, Germany
Tuesday, Nov. 15 – presentations from 10:45 a.m. to 12:00 p.m.
* ORION 1 – Inhibition of PCSK9 Synthesis Via RNA Interference: 90 Day Data From Orion-1-a Multi-center Phase-2 Randomized Controlled Trial – the presenting researcher is Kausik Ray, MD, of Imperial College in London
* GLAGOV – Effect of Evolocumab on Progression of Coronary Atherosclerosis in Statin-Treated Patients: A Placebo-Controlled Intravascular Ultrasound Trial – the presenting researcher is Steve Nissen, MD, of the Cleveland Clinic in Cleveland, Ohio
* AEGIS-1 – The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human ApoA-I, After Acute Myocardial Infarction - The ApoA-I Event Reduction in Ischemic Syndromes I Trial – the presenting researcher is C. Michael Gibson, MD, of Beth Israel Deaconess Medical Center in Boston
* Ionis-angptl3-lRx, An Antisense Inhibitor To Angiopoietin-like Protein 3 [angptl3] Reduces Plasma Angptl3 And Lipids In Healthy Volunteers With Elevated Triglycerides – the presenting researcher is Teresa Brandt, PhD, of Ionis Pharmaceuticals, Inc.
* MILANO-PILOT – Impact of Infusion of an ApoA-I HDL Mimetic on Regression of Coronary Atherosclerosis in Acute Coronary Syndrome Patients – the presenting researcher is Stephen Nicholls, MD, PhD, of South Australian Health and Medical Research Institute in Adelaide, Australia
Wednesday, Nov. 16 – presentations from 10:45 a.m. to 12:00 p.m.
* REDUCE LAP HF – Transcatheter Interatrial Shunt Device Provides Sustained Clinical Benefit at One Year in Patients with Preserved or Mildly Reduced Ejection Fraction – the presenting researcher is David Kaye, MD, PhD, of Alfred Hospital in Melbourne, Australia
* ATHENA HF – Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis Therapy in Heart Failure Trial – the presenting researcher is Javed Butler, MD, PhD, of Stony Brook University in Stony Brook, New York
* IRONOUT HF – Oral Iron Repletion effects On Oxygen Up Take in Heart Failure – the presenting researcher is Gregory Lewis, MD, of Massachusetts General Hospital in Boston
* EFFECT HF – Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Iron Deficiency and Chronic Heart Failure: A Randomized, Controlled Study – the presenting researcher is Dirk J. Van Veldhuisen, MD, of University Medical Center in Groningen, Netherlands
* MOMENTUM 3 – Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 - Primary Results of the Short Term (6 month) Cohort – the presenting researcher is Mandeep Mehra, MD, of Brigham and Women’s Hospital in Boston
* MultiSENSE – A Multi-sensor Algorithm Predicts Heart Failure Events in Patients with Implanted Devices – the presenting researcher is John P. Boehmer, MD, of Pennsylvania State University in Hershey, Pennsylvania
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.